ArticleLeukemia2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.
Registry-linked trialAbstract readMulticenter Study
In one paragraph
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07451652 (Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma), which is not on this map. Cited by 96 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 5 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Who cites it
96 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.Blood advances · 2025Pooled it
- SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma.Clinical pharmacokinetics · 2026Trial
- Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.Clinical pharmacology and therapeutics · 2026Trial
- Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.International journal of clinical oncology · 2026Trial
- Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.Journal of hematology & oncology · 2026Trial
- Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.International journal of hematology · 2026Trial
- Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.Future oncology (London, England) · 2026Trial
- Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL.Blood advances · 2025Trial
- Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.International journal of clinical oncology · 2025Trial
- Trial
- Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics.Oncoimmunology · 2026Review
- Bispecific Antibody-Based Combination Therapies for B-Cell Lymphomas: Current Evidence and Future Perspectives.International journal of cancer · 2026Review
- Next-generation immune cell engagers for B cell depletion in autoimmune diseases.Nature reviews. Drug discovery · 2026Review
- Outcomes of real-world complete responders after fixed duration glofitamab in relapsed/refractory large B-cell lymphoma.Haematologica · 2026Article
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
- Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Catherine ThieblemontAssistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France. catherine.thieblemont@aphp.fr.ORCID 0000-0002-9941-2448
Yasmin H KarimiDivision of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
Herve GhesquieresHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
Chan Y CheahSir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia.
Michael Roost ClausenVejle Hospital, Vejle, Denmark.
David CunninghamThe Royal Marsden NHS Foundation Trust, Sutton, UK.
Wojciech JurczakMSC National Research Institute of Oncology, Kraków, Poland.ORCID 0000-0003-1879-8084
Young Rok DoKeimyung University Dongsan Medical Center, Daegu, Republic of Korea.
Robin GasiorowskiConcord Hospital, University of Sydney, Sydney, Australia.ORCID 0000-0003-1225-8757
David John LewisUniversity Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK.
Tae Min KimSeoul National University Hospital, Seoul, Republic of Korea.ORCID 0000-0001-6145-4426
Marjolein van der PoelLunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Michelle Limei PoonNational University Hospital, Singapore, Singapore.
Tatyana FeldmanJohn Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA.
Kim M LintonThe Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK.
Anna SuredaClinical Hematology Department, Institut Català d'Oncologia - L'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0002-1238-6970
Martin HutchingsRigshospitalet and University of Copenhagen, Copenhagen, Denmark.
Minh H DinhAbbVie, North Chicago, IL, USA.ORCID 0000-0001-6505-8877
Nurgul KilavuzGenmab, Plainsboro, NJ, USA.
David SoongGenmab, Plainsboro, NJ, USA.
Thomas MarkGenmab, Copenhagen, Denmark.
Mariana SacchiGenmab, Plainsboro, NJ, USA.
Tycel PhillipsUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
Pieternella J LugtenburgLunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology, University Medical Center, Rotterdam, The Netherlands.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary results (median follow-up, 10.7 months) from the pivotal EPCORE
Indexed as
Antibodies, BispecificLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualPrognosisSurvival RateYoung AdultAntibodies, Bispecific
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT07451652ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.